Recent Finacing
Recent Raise
N30 Pharmaceuticals is a Boulder-based biopharmaceutical company developing N91115, an oral GSNOR inhibitor for cystic fibrosis that has completed Phase 1 dosing and enhances F508del-CFTR function in preclinical studies.
Recent Investors
Total Raised
Funding round
Investors
